Barely Significant
← all excerpts

Emerging evidence and treatment paradigm of non-small cell lung cancer.

J Hematol Oncol · 2023 · PMC10108547 · PMID 37069698

Europe PMCDOI
1
hedged sentence
0.0079
closest p · 0.2× alpha
0.0079
boldest claim

The sentences

a favorable trendp = 0.0079actually significant
Most subgroups benefited from nivolumab plus chemotherapy compared with chemotherapy alone, and the interim analysis showed a favorable trend for OS (HR = 0.57; p = 0.0079).

also in 313 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.